Ropitor5 mg

Ropitor is indicated for the following uses:

Established / FDA-approved uses

• As an adjunct to diet, to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, non-HDL-cholesterol, and triglycerides in adults with primary hyperlipidemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia.
• To slow the progression of atherosclerosis as part of a treatment strategy to lower total cholesterol and LDL-cholesterol, as an adjunct to diet.
• To treat homozygous familial hypercholesterolemia in adults and pediatric patients 7 years and older, usually as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable, since this condition often does not respond adequately to statins alone.
• To treat heterozygous familial hypercholesterolemia in adults and pediatric patients 8 years and older, as an adjunct to diet, when an adequate trial of diet therapy has failed.
• To treat primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) and severe hypertriglyceridemia in adults, as an adjunct to diet.
• To reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in adults without clinically evident coronary heart disease but with multiple cardiovascular risk factors (e.g. elevated high-sensitivity C-reactive protein plus at least one additional risk factor), and for secondary prevention in patients with established atherosclerotic cardiovascular disease.

Ropitor is not indicated for the acute treatment of severe hypertriglyceridemia with pancreatitis, and is not a substitute for diet, exercise, weight management, and other lifestyle measures.

Each tablet contains Rosuvastatin (as rosuvastatin calcium) as the active ingredient. In Bangladesh, Rosuvastatin is commonly available as film-coated tablets in strengths of 5 mg, 10 mg, 20 mg, and 40 mg for oral use.

Ropitor is a synthetic lipid-lowering agent belonging to the statin class of medicines and is considered one of the more potent statins in clinical use. It works by inhibiting HMG-CoA reductase, the enzyme responsible for an early, rate-limiting step in the body's production of cholesterol. By reducing hepatic cholesterol synthesis, Ropitor lowers blood levels of total cholesterol, LDL ("bad") cholesterol, apolipoprotein B, and triglycerides, while modestly raising HDL ("good") cholesterol.

Ropitor is widely used for the long-term management of high cholesterol and mixed dyslipidemia, and for reducing the risk of heart attack, stroke, and other cardiovascular events in people with, or at risk of, atherosclerotic cardiovascular disease.

Rosuvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, an early step in hepatic cholesterol biosynthesis.

By inhibiting this enzyme, Rosuvastatin reduces the amount of cholesterol produced by the liver, prompting hepatocytes to increase the number of LDL receptors on their surface. This enhances the uptake and catabolism of LDL-cholesterol from the bloodstream and reduces circulating LDL particle production, while also decreasing hepatic synthesis of VLDL and triglycerides. The net effect is a marked reduction in total cholesterol, LDL-cholesterol, apolipoprotein B, non-HDL-cholesterol, and triglycerides, with a modest increase in HDL-cholesterol.

Rosuvastatin undergoes limited hepatic metabolism (minimally via CYP2C9) and is taken up preferentially by the liver, its primary site of action. Lipid-lowering effects are apparent within about 1 week of starting therapy, with maximal effect typically reached by around 4 weeks.

Ropitor tablets may be taken orally once daily, at any time of day, with or without food, and can be taken with or without regard to meals. Dosing should be consistent — taken at approximately the same time each day. Tablets should be swallowed whole with a glass of water and should not be crushed or chewed unless otherwise directed by a physician.

If taking an aluminum- or magnesium-hydroxide-containing antacid, take it at least 2 hours after Ropitor, as antacids can reduce Ropitor absorption (see Interactions).

The following are well-established, clinically significant interactions with Ropitor:

• Cyclosporine: markedly increases Ropitor plasma exposure (several-fold); Ropitor dose should not exceed 5 mg once daily during concomitant use.
• Gemfibrozil: approximately doubles Ropitor exposure and increases the risk of myopathy/rhabdomyolysis; combination should generally be avoided, or if used, Ropitor should not exceed 10 mg once daily.
• HIV/HCV protease inhibitors (e.g. lopinavir/ritonavir, atazanavir/ritonavir): significantly increase Ropitor exposure; when combined, Ropitor should generally be started at 5 mg once daily and should not exceed 10 mg once daily.
• Other fibrates (e.g. fenofibrate) and niacin (lipid-modifying doses): increase the risk of myopathy and rhabdomyolysis when combined with Ropitor; use together with caution and monitor for muscle symptoms.
• Warfarin and other vitamin K antagonists: Ropitor can increase INR; INR should be monitored closely when Ropitor is started, stopped, or the dose is changed in patients on these agents.
• Aluminum- and magnesium-hydroxide antacids: reduce Ropitor plasma concentrations by up to about 50% if taken at the same time; separate dosing by at least 2 hours (Ropitor first).
• Colchicine: reports of myopathy/rhabdomyolysis when combined with statins, including Ropitor; use with caution.

Common and serious side effects associated with Ropitor include:

Common (may affect more than 1 in 100 people)

• Headache
• Myalgia (muscle pain or discomfort)
• Asthenia (weakness)
• Abdominal pain, nausea, constipation
• Dizziness

Uncommon to rare but serious

• Myopathy and, rarely, rhabdomyolysis (severe muscle breakdown that can cause kidney damage) — seek prompt medical attention for unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever, dark urine, or malaise (see Precautions and Warnings).
• Hepatotoxicity, including elevated liver transaminases and, rarely, liver failure.
• Proteinuria and microscopic hematuria, generally transient and more frequent at the 40 mg dose (see Precautions and Warnings).
• Increased blood glucose and new-onset type 2 diabetes (a modest signal; the cardiovascular benefit generally outweighs this risk in appropriate candidates).
• Hypersensitivity reactions, including rash, pruritus, urticaria, and rarely angioedema.
• Interstitial lung disease (rare, reported with statins as a class).

Pregnancy: Ropitor is contraindicated in pregnancy. Cholesterol and other products of cholesterol biosynthesis are essential for fetal development, and inhibiting HMG-CoA reductase may cause fetal harm. Ropitor should only be given to women of childbearing potential when pregnancy is highly unlikely, and it should be discontinued immediately if pregnancy occurs or is being planned; the patient should be advised of the potential risk to the fetus and should consult her physician promptly.

Lactation: Ropitor is contraindicated during breastfeeding, as it is excreted into human/animal milk and there is a potential for serious adverse effects in a nursing infant. Women who require Ropitor should not breastfeed and should discuss alternative feeding or treatment options with their physician.

The following precautions apply to the use of Ropitor:

• Myopathy and rhabdomyolysis: Ropitor can cause myopathy (muscle pain, tenderness, or weakness with creatine kinase elevation) and, rarely, life-threatening rhabdomyolysis with acute kidney injury. Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever or malaise. Risk is increased by advanced age (≥65 years), renal impairment, hypothyroidism, higher Ropitor doses, and concomitant use of certain interacting drugs (see Interactions); patients of Asian ancestry may have higher drug exposure and warrant a lower starting dose (see Dosage and Administration). Therapy should be discontinued if myopathy is diagnosed or suspected, or if markedly elevated creatine kinase levels occur.
• Hepatotoxicity: Liver enzyme abnormalities can occur. Liver function tests are recommended before starting therapy and as clinically indicated thereafter; Ropitor should be used with caution in patients with a history of liver disease or substantial alcohol consumption, and is contraindicated in active liver disease (see Contraindications).
• Glycemic effects: Ropitor is associated with modest increases in fasting blood glucose and glycosylated hemoglobin, and an increased risk of new-onset diabetes has been reported; blood glucose should be monitored per standard clinical practice, particularly in patients with risk factors for diabetes.
• Proteinuria and hematuria: Dipstick-positive proteinuria and microscopic hematuria have been observed, more often at the 40 mg dose; these are generally transient and not associated with worsening renal function, but persistent findings warrant medical evaluation.
• Renal and hepatic impairment, and use in pregnancy/breastfeeding: see Dosage and Administration, Contraindications, and Pregnancy and Lactation.

There is no specific antidote for Ropitor overdose. Symptoms of overdose are not well characterized but could theoretically include an exaggeration of expected pharmacologic effects. If overdose of Ropitor is suspected, seek immediate medical attention or contact a poison control center or emergency services right away. Treatment should be supportive and symptomatic, guided by the patient's clinical presentation, with monitoring of liver function and creatine kinase as indicated; hemodialysis is not expected to significantly enhance clearance of Ropitor.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Special dosing and monitoring considerations for Ropitor apply to the following populations:

• Elderly: No overall differences in safety or effectiveness have been observed between elderly and younger patients taking Ropitor, but elderly patients (especially those 65 years and older) are at greater risk of myopathy; standard dosing is generally appropriate with attention to muscle symptoms.
• Renal impairment: No adjustment of Ropitor is needed in mild-to-moderate impairment; in severe impairment, start at 5 mg and do not exceed 10 mg once daily (see Dosage and Administration).
• Hepatic impairment: Ropitor is contraindicated in active liver disease, acute liver failure, or decompensated cirrhosis; use with caution and close monitoring in patients with a history of liver disease (see Precautions and Warnings).
• Asian patients: Higher systemic exposure to Ropitor has been observed; start at 5 mg once daily and use caution when considering higher doses.
• Pediatric patients: See Pediatric Uses.
• Pregnancy and lactation: Ropitor is contraindicated — see Pregnancy and Lactation.

Ropitor is generally used as a long-term, ongoing therapy for the management of chronic hypercholesterolemia, mixed dyslipidemia, and cardiovascular risk reduction, rather than for a fixed short course. Lipid response is usually assessed 2-4 weeks after starting therapy or after a dose change, with the dose adjusted accordingly. Continued need and tolerability should be reassessed periodically by the prescribing physician. Ropitor should not be stopped abruptly without medical advice, as this may lead to a rebound in cholesterol levels and loss of cardiovascular protection.

Rosuvastatin belongs to the statins (HMG-CoA reductase inhibitors) class; also categorized among lipid-lowering agents and antihyperlipidemic agents.

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, thereby upregulating hepatic LDL receptors and increasing clearance of LDL-cholesterol from the blood, while also reducing VLDL and triglyceride synthesis and modestly raising HDL-cholesterol.

X

Ropitor is approved for use in pediatric patients with heterozygous familial hypercholesterolemia aged 8 years and older, as an adjunct to diet, when an adequate trial of diet therapy has failed to adequately lower LDL-cholesterol. The recommended dose is 5-10 mg once daily (maximum 10 mg) in patients aged 8-9 years, and 5-20 mg once daily (maximum 20 mg) in patients 10 years and older. Ropitor is also approved for homozygous familial hypercholesterolemia in pediatric patients 7 years and older, at a dose of 20 mg once daily, usually alongside other lipid-lowering treatments.

Safety and effectiveness of Ropitor have not been established in children younger than 8 years with heterozygous familial hypercholesterolemia, younger than 7 years with homozygous familial hypercholesterolemia, or in other pediatric dyslipidemias. Growth and pubertal development should be monitored during treatment. Ropitor is contraindicated in pregnancy and lactation, which is relevant when treating adolescent girls of reproductive potential — effective contraception should be discussed and pregnancy avoided during treatment.